Skip to main
TMDX

TMDX Stock Forecast & Price Target

TMDX Analyst Ratings

Based on 8 analyst ratings
Buy
Strong Buy 38%
Buy 38%
Hold 25%
Sell 0%
Strong Sell 0%

Bulls say

TransMedics Group Inc. is experiencing promising growth trends, with an anticipated operating margin expansion of over 16%, surpassing prior projections. The company is poised for significant revenue increases, projecting a 35.2% year-over-year growth in US organ transplant volume and a 40.5% rise in US sales for Q4, which exceed consensus estimates. Additionally, favorable factors such as new product launches, accelerating adoption rates in heart and lung transplants, and stronger international growth contribute to the overall positive outlook for TransMedics Group’s performance.

Bears say

TransMedics Group Inc. has reported Q3 product revenues of $87.7 million and service revenues of $56.1 million, both showing year-over-year growth of over 30%, yet falling short of consensus estimates by approximately $1 million, indicating potential challenges in market penetration and sales force scalability. Furthermore, the company's daily flights and flight hours experienced sequential declines, aligning more with Q1/25 metrics rather than showing sustained growth, which raises concerns about operational efficiency and market presence. Additionally, the firm faces various risks including competition, regulatory challenges, and the effectiveness of its commercialization strategy, all of which contribute to a negative outlook amid the marginal top-line miss and the downward adjustment in share value.

TMDX has been analyzed by 8 analysts, with a consensus rating of Buy. 38% of analysts recommend a Strong Buy, 38% recommend Buy, 25% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Transmedics Group Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Transmedics Group Inc (TMDX) Forecast

Analysts have given TMDX a Buy based on their latest research and market trends.

According to 8 analysts, TMDX has a Buy consensus rating as of Jan 9, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $144.25, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $144.25, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Transmedics Group Inc (TMDX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.